AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20012601 — intervention group
Group type: COMPARATOR
Intervention: Control (verapamil 60 mg without lovastatin)
Number of subjects: 14
Study 17413685 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC114/ritonavir (TMC114/r)
Number of subjects: 278
Study 17413685 — intervention group
Group type: COMPARATOR
Intervention: Control PI drug(s) (CPI)
Number of subjects: 278
Study 16319551 — intervention group
Group type: EXPERIMENTAL
Intervention: Red grape polyphenol extract (600 mg)
Number of subjects: 30
Study 16319551 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20 ml of water)
Number of subjects: 30
Study 12435182 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed cooled-tip catheter
Number of subjects: 100
Study 12435182 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-mm-tip catheter
Number of subjects: 100
Study 10492627 — intervention group
Group type: EXPERIMENTAL
Intervention: FAMTX (5-fluorouracil, doxorubicin, methotrexate) before surgery
Number of subjects: 56
Study 10492627 — intervention group
Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 56
Study 8568486 — intervention group
Group type: EXPERIMENTAL
Intervention: Formalin‐inactivated, alum‐adjuvanted hepatitis A vaccine (25 units, MSD) at 0, 24 weeks (group I)
Number of subjects: 60
Study 8568486 — intervention group
Group type: EXPERIMENTAL
Intervention: Formalin‐inactivated, alum‐adjuvanted hepatitis A vaccine (25 units, MSD) at 0, 2, 24 weeks (group II)
Number of subjects: 60
Study 2007359 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 200 micrograms four times daily
Number of subjects: 147
Study 2007359 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 300 micrograms four times daily
Number of subjects: 147
Study 2007359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 2007359 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher density of H. pylori
Number of subjects: 147
Study 2007359 — intervention group
Group type: EXPERIMENTAL
Intervention: Degree of gastritis
Number of subjects: 147
Study 6284190 — intervention group
Group type: EXPERIMENTAL
Intervention: Misonidazole (MISO) at 0.15 g/m2
Number of subjects: 48
Study 6284190 — intervention group
Group type: EXPERIMENTAL
Intervention: Misonidazole (MISO) at 0.30 g/m2
Number of subjects: 48
Study 6284190 — intervention group
Group type: EXPERIMENTAL
Intervention: Misonidazole (MISO) at 0.45 g/m2
Number of subjects: 48
Study 6284190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 6284190 — intervention group
Group type: EXPERIMENTAL
Intervention: Misonidazole (MISO)
Number of subjects: 48
Study 30611292 — intervention group
Group type: EXPERIMENTAL
Intervention: M4bH and IAQ feedback
Number of subjects: 1800
Study 30611292 — intervention group
Group type: EXPERIMENTAL
Intervention: M4bH alone
Number of subjects: 1800
Study 30611292 — intervention group
Group type: COMPARATOR
Intervention: Usual services only
Number of subjects: 1800
Study 28111429 — intervention group
Group type: EXPERIMENTAL
Intervention: Necitumumab plus gemcitabine and cisplatin (neci+GC)
Number of subjects: 84
Study 28111429 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine and cisplatin (GC)
Number of subjects: 84
Study 23743219 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% levobupivacaine
Number of subjects: 52
Study 23743219 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 52
Study 23406936 — intervention group
Group type: COMPARATOR
Intervention: Mometasone furoate delivered by dry powder inhaler (MF-DPI) 100 microgram q.d. P.M.
Number of subjects: 1445
Study 23406936 — intervention group
Group type: COMPARATOR
Intervention: Mometasone furoate delivered by dry powder inhaler (MF-DPI) 200 microgram q.d. P.M.
Number of subjects: 1445
Study 23406936 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate delivered by dry powder inhaler (MF-DPI) 100 microgram
Number of subjects: 1445
Study 23406936 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate delivered by dry powder inhaler (MF-DPI) 200 microgram
Number of subjects: 1445
Study 21543375 — intervention group
Group type: EXPERIMENTAL
Intervention: Low 25-hydroxy-vitamin D (25(OH)D) levels
Number of subjects: 548
Study 21543375 — intervention group
Group type: EXPERIMENTAL
Intervention: Low 25-hydroxy-vitamin D (25(OH)D) concentration
Number of subjects: 548
Study 19084440 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (4 RCTs, 2 uncontrolled trials)
Number of subjects: 939
Study 19084440 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate/divalproex sodium (2 RCTs, 1 uncontrolled trial, 2 retrospective chart reviews)
Number of subjects: 939
Study 19084440 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (only uncontrolled studies)
Number of subjects: 939
Study 19084440 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide (only uncontrolled studies)
Number of subjects: 939
Study 17561515 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural naloxone with sufentanil in ropivacaine (Group N)
Number of subjects: 50
Study 17561515 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil in ropivacaine alone (Group C)
Number of subjects: 50
Study 17561515 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Group N and Group C)
Number of subjects: 50
Study 15220654 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Number of subjects: 40
Study 15220654 — intervention group
Group type: EXPERIMENTAL
Intervention: One‐Up Bond F
Number of subjects: 40
Study 15220654 — intervention group
Group type: EXPERIMENTAL
Intervention: Unifil Bond
Number of subjects: 40
Study 15220654 — intervention group
Group type: EXPERIMENTAL
Intervention: ABF
Number of subjects: 40
Study 15220654 — intervention group
Group type: COMPARATOR
Intervention: Control group (positive and negative controls)
Number of subjects: 40
Study 11487656 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to music (musicians)
Number of subjects: 0
Study 11487656 — intervention group
Group type: COMPARATOR
Intervention: Listening to music (non-musicians)
Number of subjects: 0
Study 11487656 — intervention group
Group type: COMPARATOR
Intervention: Resting conditions (musicians)
Number of subjects: 0
Study 11487656 — intervention group
Group type: COMPARATOR
Intervention: Resting conditions (non-musicians)
Number of subjects: 0
Study 11487656 — intervention group
Group type: COMPARATOR
Intervention: Listening to neutral text (musicians)
Number of subjects: 0
Study 11487656 — intervention group
Group type: COMPARATOR
Intervention: Listening to neutral text (non-musicians)
Number of subjects: 0
Study 9728827 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciaglia method (gradual dilation)
Number of subjects: 80
Study 9728827 — intervention group
Group type: COMPARATOR
Intervention: Portex method (single dilation)
Number of subjects: 80
Study 9728827 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 80
Study 8906943 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (1.5 to 2.0 mg/kg/day) administered orally or as continuous intravenous drip for the first three days followed by oral therapy along with standard treatment.
Number of subjects: 0
Study 8906943 — intervention group
Group type: COMPARATOR
Intervention: Best medical care (BMC) for ICVD control cases.
Number of subjects: 0
Study 2319049 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum (delivered ad lib or on a fixed regimen)
Number of subjects: 1218
Study 2319049 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 1218
Study 2319049 — intervention group
Group type: COMPARATOR
Intervention: No gum
Number of subjects: 1218
Study 2319049 — intervention group
Group type: COMPARATOR
Intervention: Self-guided behavioral treatment (self-selected modules, randomly administered modules, no modules)
Number of subjects: 1218
Study 2319049 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum (for men)
Number of subjects: 1218
Study 2319049 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum (for women)
Number of subjects: 1218
Study 508553 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of metoclopramide (5 and 10 mg)
Number of subjects: 0
Study 508553 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of metoclopramide (aqueous solution)
Number of subjects: 0
Study 508553 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of metoclopramide (slow release tablet)
Number of subjects: 0
Study 31679512 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education program (six sessions, 10 h) and group physical exercise (18 sessions program carried out in six weeks, 18 h)
Number of subjects: 0
Study 31679512 — intervention group
Group type: COMPARATOR
Intervention: Usual care physiotherapy treatment
Number of subjects: 0
Study 28716153 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 1000
Study 26375804 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Interaction Project (VIP)
Number of subjects: 438
Study 26375804 — intervention group
Group type: COMPARATOR
Intervention: Building Blocks (BB)
Number of subjects: 438
Study 26375804 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 438
Study 24135054 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS and venlafaxine
Number of subjects: 540
Study 24135054 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS and venlafaxine
Number of subjects: 540
Study 24135054 — intervention group
Group type: COMPARATOR
Intervention: Venlafaxine alone
Number of subjects: 540
Study 24135054 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 540
Study 20126968 — intervention group
Group type: EXPERIMENTAL
Intervention: HEPA programme (8-week health enhancing and physical activity programme)
Number of subjects: 20
Study 20126968 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 20
Study 18945396 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological treatment
Number of subjects: 3178
Study 18945396 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic treatment (SSRIs)
Number of subjects: 3178
Study 18945396 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic treatment (other antidepressants)
Number of subjects: 3178
Study 18945396 — intervention group
Group type: COMPARATOR
Intervention: Pharmacologic treatment
Number of subjects: 3178
Study 16628714 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim
Number of subjects: 20
Study 16628714 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenograstim
Number of subjects: 20
Study 16628714 — intervention group
Group type: COMPARATOR
Intervention: Control (blood donors)
Number of subjects: 20
Study 14650863 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux for prevention of VTE in orthopedic surgical patients (PENTHIFRA Plus)
Number of subjects: 0
Study 14650863 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux for prevention of VTE in high-risk abdominal surgical patients (PEGASUS and APOLLO)
Number of subjects: 0
Study 14650863 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux for prevention of VTE in medical patients (ARTEMIS)
Number of subjects: 0
Study 14650863 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux for treatment of VTE (MATISSE DVT and MATISSE PE)
Number of subjects: 0
Study 14650863 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux for treatment of acute coronary syndromes (PENTALYSE and PENTUA)
Number of subjects: 0
Study 14650863 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux in orthopedic prophylactic and nonorthopedic clinical programs
Number of subjects: 0
Study 10818057 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (chlorthalidone-based treatment)
Number of subjects: 4126
Study 10818057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4126
Study 10818057 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with hypokalemia
Number of subjects: 4126
Study 10818057 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with normal potassium levels
Number of subjects: 4126
Study 8788488 — intervention group
Group type: EXPERIMENTAL
Intervention: N,N-dimethyltryptamine (DMT)
Number of subjects: 0
Study 8788488 — intervention group
Group type: COMPARATOR
Intervention: Pindolol pre-treatment
Number of subjects: 0
Study 1521944 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (50 mg/24 h)
Number of subjects: 15
Study 1521944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 6442971 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG and 5‐fluorouracil alone (regimen A)
Number of subjects: 168
Study 6442971 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG and 5‐fluorouracil in combination with hydroxyurea, methyl‐CCNU and mitomycin C (regimen B)
Number of subjects: 168
Study 6442971 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox method for linear regression analysis on non‐parametric data
Number of subjects: 168
Study 29603657 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Glycemic Index (LGI) diet
Number of subjects: 122
Study 29484469 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-day antibiotic therapy
Number of subjects: 410
Study 29484469 — intervention group
Group type: COMPARATOR
Intervention: 15-day antibiotic therapy
Number of subjects: 410
Study 27491220 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp acupuncture (performed during the operation from specific acupuncture points)
Number of subjects: 84
Study 27491220 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp acupuncture
Number of subjects: 84
Study 27491220 — intervention group
Group type: COMPARATOR
Intervention: Control group (no scalp acupuncture)
Number of subjects: 84
Study 24524697 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycemic index (LGI) meal (glycemic index = 37)
Number of subjects: 12
Study 24524697 — intervention group
Group type: COMPARATOR
Intervention: Mixed meal (CON; glycemic index ∼57)
Number of subjects: 12
Study 22922781 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for symptomatic convergence insufficiency
Number of subjects: 221
Study 20877732 — intervention group
Group type: EXPERIMENTAL
Intervention: Twin blocks
Number of subjects: 20
Study 20877732 — intervention group
Group type: COMPARATOR
Intervention: Flat occlusal splints
Number of subjects: 20
Study 17549327 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural training programme
Number of subjects: 75
Study 17549327 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity programme
Number of subjects: 75
Study 17549327 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 75
Study 17532965 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous surfactant instillation
Number of subjects: 29
Study 17532965 — intervention group
Group type: COMPARATOR
Intervention: Control group (no surfactant instillation)
Number of subjects: 29
Study 15354376 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 0
Study 15354376 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypericum perforatum (St. John's Wort)
Number of subjects: 0
Study 15354376 — intervention group
Group type: EXPERIMENTAL
Intervention: S-adenosyl-methionine
Number of subjects: 0
Study 15354376 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate
Number of subjects: 0
Study 15354376 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Hydroxytryptophan
Number of subjects: 0
Study 15354376 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study 15354376 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 0
Study 15354376 — intervention group
Group type: EXPERIMENTAL
Intervention: Light therapy
Number of subjects: 0
Study 15354376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11432682 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (2 g) as a single intravenous dose at anesthetic induction
Number of subjects: 103
Study 11432682 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin (1 g) plus clindamycin (0.6 g) administered intravenously at anesthetic induction and for two more doses at 8‐hourly intervals for a total of 3 days
Number of subjects: 103
Study 9355946 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy shockwave lithotripsy (Shock Tube C)
Number of subjects: 336
Study 9355946 — intervention group
Group type: COMPARATOR
Intervention: Low-energy shockwave lithotripsy (Siemens Lithostar)
Number of subjects: 336
Study 8407423 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant cisplatin and radiotherapy
Number of subjects: 0
Study 8407423 — intervention group
Group type: EXPERIMENTAL
Intervention: Single agent cisplatin and radiotherapy
Number of subjects: 0
Study 8407423 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-5-FU and split course radiotherapy
Number of subjects: 0
Study 8407423 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 2439827 — intervention group
Group type: EXPERIMENTAL
Intervention: bopindolol (1-2 mg daily)
Number of subjects: 33
Study 2439827 — intervention group
Group type: COMPARATOR
Intervention: atenolol (50-100 mg daily)
Number of subjects: 33
Study 30608598 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy using gemcitabine and S-1
Number of subjects: 360
Study 30608598 — intervention group
Group type: COMPARATOR
Intervention: Upfront surgery
Number of subjects: 360
Study 28964662 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine (LT-4) replacement therapy for 2 months
Number of subjects: 40
Study 27510524 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week interval after chemoradiotherapy
Number of subjects: 31
Study 27510524 — intervention group
Group type: COMPARATOR
Intervention: 12-week interval after chemoradiotherapy
Number of subjects: 31
Study 27510524 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (6-week and 12-week)
Number of subjects: 31
Study 23815764 — intervention group
Group type: EXPERIMENTAL
Intervention: WCA history (67.5% of participants)
Number of subjects: 114
Study 23815764 — intervention group
Group type: EXPERIMENTAL
Intervention: WCA
Number of subjects: 114
Study 23815764 — intervention group
Group type: COMPARATOR
Intervention: no-WCA
Number of subjects: 114
Study 23195006 — intervention group
Group type: EXPERIMENTAL
Intervention: CNI-free maintenance therapy
Number of subjects: 75
Study 23195006 — intervention group
Group type: COMPARATOR
Intervention: Low-dose CNI therapy
Number of subjects: 75
Study 23195006 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL)
Number of subjects: 75
Study 23195006 — intervention group
Group type: EXPERIMENTAL
Intervention: Glomerular filtration rates (GFR)
Number of subjects: 75
Study 19200421 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (titrated to 200 mg/d)
Number of subjects: 124
Study 19200421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 19200421 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 124
Study 17550365 — intervention group
Group type: EXPERIMENTAL
Intervention: Math instruction group
Number of subjects: 61
Study 17550365 — intervention group
Group type: COMPARATOR
Intervention: Standard psychoeducational care group
Number of subjects: 61
Study 17550365 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental instruction workshops
Number of subjects: 61
Study 17550365 — intervention group
Group type: EXPERIMENTAL
Intervention: Achenbach Child Behavior Checklist
Number of subjects: 61
Study 15376805 — intervention group
Group type: EXPERIMENTAL
Intervention: Probability-learning phase preceding reasoning tasks
Number of subjects: 0
Study 15376805 — intervention group
Group type: COMPARATOR
Intervention: Standard conditional inferences, card choices in the Wason selection task, and quantifiers from syllogisms
Number of subjects: 0
Study 11289345 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronised fenofibrate (200 mg/day)
Number of subjects: 418
Study 11289345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 418
Study 9530599 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigating solution with heparin-sodium (10 IU/mL)
Number of subjects: 72
Study 9530599 — intervention group
Group type: COMPARATOR
Intervention: Regular irrigating solution (control)
Number of subjects: 72
Study 7799578 — intervention group
Group type: EXPERIMENTAL
Intervention: Dressings containing a layer of aerosil 2-3 mm thick
Number of subjects: 0
Study 7799578 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 3240892 — intervention group
Group type: EXPERIMENTAL
Intervention: Gynatren
Number of subjects: 192
Study 3240892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study 30913208 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (4g/d)
Number of subjects: 567
Study 30913208 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (100mg/d)
Number of subjects: 567
Study 30913208 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for both fish oil and aspirin)
Number of subjects: 567
Study 29130716 — intervention group
Group type: EXPERIMENTAL
Intervention: Processed quinoa (Kuska Active product)
Number of subjects: 30
Study 29130716 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 30
Study 26341548 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 400 μg salbutamol in standard posture
Number of subjects: 22
Study 26341548 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 200 μg salbutamol in standard posture
Number of subjects: 22
Study 26341548 — intervention group
Group type: COMPARATOR
Intervention: Inhalation of salbutamol in forward leaning posture
Number of subjects: 22
Study 23910574 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 0
Study 20713345 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart 70/30 (BIAsp 30) + metformin
Number of subjects: 280
Study 20713345 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine + metformin + secretagogues
Number of subjects: 280
Study 20713345 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart 70/30 (BIAsp 30)
Number of subjects: 280
Study 20713345 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 280